Tel Aviv‑based Cassidy Bio closed an $8 million seed round to develop an AI platform that predicts optimal combinations of guide RNAs, editing enzymes and delivery modalities for therapeutic genome editing. Ahren Innovation Capital led the financing with participation from Lool Ventures, 10D VC and AIon Labs. Cassidy’s approach combines a genomic foundation model trained on proprietary wet‑lab data and population genomics to address target selection, delivery, efficacy and specificity—areas that currently slow translation of genome editors into reliable medicines. CEO Rom Kshuk said the platform aims to improve early‑stage design confidence and scale therapeutic genome editing beyond one‑off successes toward clinically reliable, broadly applicable programs.